Advances in anlotinib combined with cranial radiotherapy for brain metastases from advanced non-small cell lung cancer
Year: 2026
Type: article
Abstract: Non-small cell lung cancer (NSCLC) has a persistently high incidence and mortality rate, and brain metastasis is one of the common complications with a poor prognosis. At present, cranial radiotherapy is a key treatment for controlling the progression of brain metastases, but its efficacy remains limited. Anlotinib is a multitarget tyrosine kinase inhibitor that can significantly prolong the survival of patients with advanced NSCLC. Clinical studies have found that anlotinib combined with cranial radiotherapy can delay the progression of brain metastases with good safety. This review mainly discusses the mechanisms and clinical efficacy of this combination strategy in NSCLC with brain metastases, aiming to provide a new and effective therapeutic option for these patients.
Source: Frontiers in Neurology
Institution: Chongqing Medical University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236731007
